Evidence for the presence of stem cell-like progenitor cells in human adult pancreas

Min Zhao, Stephanie A Amiel, Michael R Christie, Paolo Muiesan1, Parthi Srinivasan1, Wendy Littlejohn1, Mohamed Rela1, Matthew Arno2, Nigel Heaton1 and Guo Cai Huang

Department of Diabetes, Endocrinology and Internal Medicine, King’s College London School of Medicine, Bessemer Road, London SE5 9PJ, UK
1Institutes of Liver Studies, King’s College London School of Medicine, London SE5 9PJ, UK
2School of Biomedical and Health Sciences, King’s College London, Genomics Centre, London SE1 9NH, UK

(Correspondence should be addressed to G C Huang; Email: guo.huang@kcl.ac.uk)

Abstract

The origin of cells replacing ageing β-cells in adult life is unknown. This study assessed the expression of classic stem cell markers: Oct4, Sox2 and CD34 in islet-enriched fractions versus exocrine cell-enriched fractions from 25 adult human pancreases following human islet isolation. Expression of Oct4, Sox2 and CD34 mRNAs was found in all cell samples, with no significant differences between endocrine and exocrine cell fractions. Immunohistochemical staining for Oct4, Sox2 and CD34 proteins. The numbers of Oct4ve and Sox2ve cells varied among donors and were ~1–200 and 1–30 per 100 000 pancreatic cells respectively.


Introduction

Islet cell death leads to insulin deficiency and diabetes – both the insidious loss of insulin secretion over time in the evolution of Type 2 diabetes and the immunological loss of all insulin-secreting cells in Type 1. The ability, at least in the short term, to restore β-cells in Type 1 diabetes by islet transplantation (Shapiro et al. 2000) has renewed interest in attempts to find β-cell surrogates. There are far fewer organ donors than people with diabetes and, at least in its present form, islet transplantation remains inefficient (Close et al. 2005, Shapiro et al. 2006) and more cells to transplant are needed. At the same time, understanding the origins of new islet β-cells in life may help devise ways of slowing down the progression of Type 2 diabetes. The presence of adult stem cells or pancreatic-specific progenitor cells in human pancreas is controversial. In animals, the β-cell population does increase following pancreas duct ligation (Wang et al. 1995) or pancreatectomy (Starich et al. 1991), in Type 2 diabetes, in obesity (Parsons et al. 1995, Chua et al. 2002) and during pregnancy (Hayashi et al. 2003) when demand for insulin is increased, showing some capacity for regeneration of β-cells during adulthood. However, the origin of the cells that replace the ageing β-cells is not clear. Lineage-tracing experiments in rodents indicate that mature β-cells are able to divide to generate new β-cells (Dor et al. 2004). However, more recent data suggest that there are other sources for new β-cells in the pancreas (Bonner-Weir et al. 2004, Paris et al. 2004). The ex vivo expansion of islet cells is thought to occur through epithelial-to-mesenchymal transition (Gershengorn et al. 2004). It has been shown that some pancreatic cells can redifferentiate into insulin-producing cells but the origin of these new cells is not known. In a previous study following ex vivo expansion of human pancreatic non-endocrine cells transplanted into a diabetic severe combined immunodeficiency (SCID) mouse model, we showed that a small portion of the expanded cells expressed insulin following differentiation induction in vitro, with further development of insulin-producing cells following transplantation. IPF1 gene transfection increased the number of insulin-expressing cells, possibly by inducing differentiation of those cells with pluripotency (Zhao et al. 2005). New islet cells can also be generated from adult pancreatic ductal cells of mice (Ramiya et al. 2000) and humans (Bonner-Weir et al. 2000, Gao et al. 2003, Yatoh et al. 2007), again arguing for the presence of stem cell-like progenitor cells in adult pancreas. Identification of these progenitor cells, particularly from human adult pancreas, would be of great interest for the generation of insulin-producing cells ex vivo to treat diabetes or to develop means to expand these cells in Type 2 patients to increase their β-cell mass. The use of adult progenitor cells reduces the risk of tumorigenicity, in comparison with cells derived from embryonic stem (ES) cells (Fujikawa et al. 2005).
Large quantities of adult human pancreatic non-endocrine cells are readily available and are currently discarded from islet isolation programmes. Identification of adult pancreatic tissue-specific progenitor cells from this source of tissues would potentially provide a valuable resource for the generation of insulin-producing cells for human transplantation. In this study, we sought evidence for the presence of the classical stem cell marker proteins, Oct4, Sox2 and CD34 in fractions of tissues from human islet isolation. Oct4 and Sox2 are transcription factors essential for maintaining the pluripotency of stem cells (Scholer et al. 1990, Ellis et al. 2004) and CD34 is the marker of haematopoietic progenitor cells (Lu et al. 2007). In order to determine the localisation of these potential stem cell-like cells, we examined sections of human pancreas for the presence of Oct4$^+$ and Sox2$^+$ cells, and their co-localisation with the duct cell marker CK19, the β-cell marker insulin, the haematopoietic progenitor cell markers CD34, CD133, and the neural stem cell marker, nestin.

**Materials and Methods**

Human pancreases were obtained for research with informed consent from the families of organ donors and this study was approved by the Ethics Committee of King’s College Hospital, London. Twenty-five pancreas organs (10 males and 15 females) from conventional (brain death) organ donors, without diabetes symptoms, were used in this study. The donor age ranges were 22–62 years with a mean age of 42.3 ± 0.93 years. The cold ischaemia time was 5.91 ± 2.15 h.

Human pancreases were retrieved by experienced surgeons, using standard techniques for organ retrieval for whole organ transplantation. In brief, after cross-clamping, pancreases were kept cold with ice pads in situ. The pancreas was perfused with 1 l ice-cold Marshall’s solution in the body and 1 l University of Wisconsin Solution (UWS) on the bench after removal, before being delivered to our Human Cell Isolation Unit, in pre-oxygenised perfluorocarbon (PFC)/(UWS) two layer solutions on ice, for islet isolation.

Human islet isolation was carried out as previously described (Huang et al. 2004). In brief, each pancreas was weighed and dissected from surrounding fat and digested with collagenase (Liberase, Roche Diagnostics) injected via the main pancreatic duct and gentle shaking. The digestion was stopped by cooling and diluting with cold MEM medium when the islets were perceived as being free of exocrine tissue but still intact. The islets in the digests were then enriched by continuous gradient centrifugation on a cooled Cobe centrifuge (Gambro BCT, Gloucester, UK). Exocrine cell-enriched fractions were taken from the bottom of Cobe centrifuge bag following the separation of human islets. Portions of islet- and exocrine-enriched fractions were lysed in the RNA lysis buffer (Promega) and stored at −80 °C until total RNA isolation.

**Semi-quantitative RT-PCR**

Total RNA was isolated using an RNA Miniprep Kit (Promega) and quantified using a spectrometer (Gene Quant II, Pharmacia Biotech) at 260 nm wavelength. The messenger RNA (mRNA) in 100 ng total RNA was converted into first-strand cDNA using reverse transcriptase (Invitrogen) in a volume of 20 μl. The hot-start (Qiagen), RT-PCR used the following parameters: 95 °C for 15 min for 1 cycle and then 94 °C for 45 s, 50–62 °C for 1 min and 72 °C 1–3 min for 20–35 cycles. RT-PCR primers for the target genes (human preproinsulin gene (435 bp), Oct4 (429 bp), Sox2 (341 bp), CD34 (474 bp) and the reference gene human β-actin (664 bp)) are listed in Table 1. Human β-actin gene PCR was done in parallel as an internal control. DNA relative quantity was analysed using a gel program (version 3.0 computer analyzer of Media Cybernetics, LP, Silver, Spring, MD, USA) and expressed relative to the density of β-actin gene PCR product as described previously (Zhao et al. 2005).

**Quantitative PCR**

Q-PCR was performed with the LightCycler-2 (Roche Diagnostics) using SYBR Green I fluorescence Kit (Roche Diagnostics). The genes were amplified in duplicate and at least three donors’ cDNAs were tested for each set of experiments, according to the manufacturer’s instructions. Briefly, the master reaction mix with the solutions from the

**Table 1** PCR primer sets

<table>
<thead>
<tr>
<th>Name of primer</th>
<th>Primer sequences</th>
<th>Product length (bp)</th>
</tr>
</thead>
<tbody>
<tr>
<td>H β-actin F</td>
<td>5′ CCCAGATCATGTTGAGACC 3′</td>
<td>664</td>
</tr>
<tr>
<td>H β-actin R</td>
<td>5′ CCACACAGTAGATCGGCCTGCTACG 3′</td>
<td>341</td>
</tr>
<tr>
<td>H Sox2 F</td>
<td>5′ CGGGCCGCCACCAAAAGCA 3′</td>
<td>429</td>
</tr>
<tr>
<td>H Sox2 R</td>
<td>5′ ACCCGGTCGATGCATTTG 3′</td>
<td>474</td>
</tr>
<tr>
<td>H Oct4 F</td>
<td>5′ GGTGCGGCCGCCTCCCTTCC 3′</td>
<td>435</td>
</tr>
<tr>
<td>H Oct4 R</td>
<td>5′ GACAATGCGGTCCGGTTTTCAG 3′</td>
<td></td>
</tr>
<tr>
<td>H CD34 F</td>
<td>5′ GCTGGGCGGCCCTCCCTTCC 3′</td>
<td></td>
</tr>
<tr>
<td>H CD34 R</td>
<td>5′ CCTGCGCCTGGCCGTTCCTTTTCT 3′</td>
<td></td>
</tr>
<tr>
<td>INS F</td>
<td>5′ CATAAGACATGGTTCG 3′</td>
<td></td>
</tr>
<tr>
<td>INS R</td>
<td>5′ CTTGTTTCAAGGGGCTATTC 3′</td>
<td></td>
</tr>
</tbody>
</table>
kit was prepared and the appropriate amounts of template DNA and 0·25 μM primers were added in a total volume of 20 μl. PCR grade water was used as a negative control as described previously (Zhao et al. 2005).

Immunocytohistochemical staining

Sections of pancreas were removed before the cannulation for collagenase injection and snap frozen in liquid N₂ and stored at −80 °C until processing. Cryosections at 5 μm intervals were prepared and were stained for Oct4 and Sox2 respectively. The sections were then blocked with biotin–avidin system (Vector Laboratories, Peterborough, UK) to prevent cross-staining to the previous antigen, followed by a second staining for insulin, CK19, nestin, CD34, CD133 or staining for Sox2 to Oct4 staining sections and vice versa respectively as described previously (Zhao et al. 2005). Negative controls were performed by replacing the first antibodies with same origin and same isotype antibodies against other non-related antigens. Oct4 and Sox2 positive cells and total cells in the same field were counted. The cells in 10 consecutive fields per section, 5 sections per donor pancreas and 5 donor pancreases were counted to assess the percentage of Oct4⁺ve and Sox2⁺ve cells.

Antibodies

The monoclonal antibody to human insulin (clone K36aC10) and the antibody to Sox2 (rabbit anti-human Sox2) were purchased from Sigma. The antibodies against Oct4 (goat polyclone, sc-8629) and CK19 (monoclonal, sc-6278) were purchased from Santa Cruz, Biotechnology (Santa Cruz, CA, USA), while the nestin antibody (monoclonal, MAB5326) was from Chemicon International (Temecula, CA, USA). The antibody to human CD34 (monoclonal QBEND/10) was from AbD Serotec (MorphoSys, UK) and the anti-human CD133/2 pure (monoclone, # 293C3) was from Miltenyi Biotec GmbH (Bergisch Gladbach, Germany).

Data analysis

All data are expressed as mean±s.d. and analysed using the ANOVA computer program. Student's t-test was used for comparison between two groups. The significance level was set at P=0·05.

Results

Expression of Oct4, Sox2 and CD34 mRNAs in pancreatic tissues and their relationship with donor age

All of the cell samples from the 25 human pancreases showed the expression of mRNAs of Oct4, Sox2 and CD34 by RT-PCR. The expression level of these genes was variable amongst the donors and was not particularly associated with islet cell fractions, nor with exocrine cell fractions (Fig. 1A). The PCR products of Oct4 and Sox2 were partially sequenced and confirmed to be authentic according to the published sequences (Oct4: NM_002701, Sox2: NM_003106).

Quantitative PCR was performed on Oct4, Sox2 and CD34 using human β-actin as a control. The relevant expression levels were expressed as copies per 1000 copies of β-actin mRNA. The expression levels for the markers were variable among the preparations, ranging from 0·02 to 9 copies for Oct4 and 0·0004 to 0·2 copies for the Sox2 per 1000 copies of human β-actin mRNA. There was a positive correlation between the expressions of the two markers (a coefficient factor R=0·613, P=0·01). Although there was a trend for higher expression from younger donors, this did not achieve significance across the range of donor ages (Fig. 1B). The expression levels were not significantly different between islet and exocrine cell fractions (Fig. 1C). The expressions of Oct4 and Sox2 were not correlated with body mass indexes of their donors (data not shown).

Expression of Oct4 and Sox2 protein in pancreatic tissues

The tissue sections from five donors were first stained for Oct4 (Fig. 2A) or Sox2 (Fig. 2D) proteins and then restained for CK19 (Fig. 2B and E), insulin and nestin respectively. The estimated frequency of the Oct4⁺ve cells ranged 1–200 cells/100 000 pancreatic cells, varying by donor, while numbers of Sox2⁺ve cells, also varied between donors, were estimated at 1–30 cells/100 000 pancreatic cells. The majority of Oct4⁺ve and Sox2⁺ve cells were located either within small pancreatic ductal structures or close to them; the majority of them were cytosolic staining (Fig. 2A and D), with small numbers of Oct4⁺ve (Fig. 2A) or Sox2⁺ve (Fig. 2D) proteins and then restained for CK19 (Fig. 3B and C) and Sox2 (Fig. 3A and D) and CD133 proteins (data not shown). Oct4⁺ve and Sox2⁺ve cells were not co-expressed with CK19 (Fig. 2C, F) and CD133 (Fig. 3A and D), while CD34⁺ve cells did not co-express ductal cell markers CK19 (Fig. 2G, I) and CD133 (Fig. 3E, F) in the adult human pancreases as assessed by immunohistochemical staining (n=5). Human pancreatic consecutive sections were used to analyse the co-localisation of CD34 and CD133 antigens using CK19 as a comparing marker. The double staining for CD34 and CD133 proved very difficult as both monoclonal antibodies were of mouse origin. CD34⁺ve cells did not co-express CD133 protein, neither with CK19 (Fig. 4) nor with insulin and nestin (data not shown).
Figure 1  (a) A typical semi-quantitative RT-PCR amplification of Oct4, Sox2 and CD34 from both islet-enriched fractions (left 4 lanes) and exocrine cell-enriched fractions (right 4 lanes) following the human islet preparations shows the presence of these markers in both cell fractions. Actin is used as an internal control for the cDNA used in the RT-PCR. The central lane is the molecular marker. Pancreas donor was a female, age 48 years.

(b) Quantitative RT-PCR analyses on the expression of Oct4, Sox2 and CD34 mRNA in cell samples from 25 donors, plotting against donor age. RT-PCR was performed on cDNA templates, synthesised from 100 ng total RNA each of both islet and exocrine cells (per donor). Solid circle represents CD34, solid square represents Sox2 and solid triangle represents Oct4. Please note that CD34 and Oct4 were against the left Y-axis while Sox2 was against the right Y-axis.

(c) Quantitative RT-PCR analyses show the expression levels of Oct4, Sox2 and CD34 gene in islet cell- and exocrine cell-enriched samples from four human islet preparations.
Discussion

The mechanisms by which β-cell mass is maintained in adulthood are not yet known and the origin of new β-cells to replace the ageing β-cells is the focus of intensive research (Lipsett et al. 2006, Xu et al. 2006). During pancreas development, endocrine cells are thought to bud off the pancreatic ducts (Slack 1995). Whether some stem cell-like cells may remain in the ductal structures is still unknown. It is well established that duct cell neogenesis takes place in adult animal models in settings where β-cell mass does expand, e.g. in pancreatic duct ligation (Wang et al. 1995) or following > 90% pancreatectomy (Starich et al. 1991), but again the source of the new cells is not known. Whether stem cells are retained in the adult pancreatic ducts, and are then responsible for the neogenesis, remains unanswered and uncertain. Our data are compatible with the hypothesis that stem cells are to be found in the adult pancreas. We found mRNA for the classic stem cell markers Oct4 and Sox2 in cells derived from both islet and exocrine cell-enriched fractions following human islet preparations.

Oct4 and Sox2 are both expressed in inner cell mass stem cells and are critical in maintaining the pluripotency of stem cells (Scholer et al. 1990, Ellis et al. 2004, Ferri et al. 2004). In the mouse, Oct4 is highly expressed in the totipotent inner cell mass, germ cells, undifferentiated ES cells and undifferentiated embryonal carcinoma cells (Hong et al. 2004). Oct4 and Sox2 have been shown to jointly regulate the Nanog...
gene, another transcription factor critical to the pluripotenti-
ality of stem cells (Kuroda et al. 2005). Reduction of the
expression of Oct4 and Nanog leads to differentiation (Hough
et al. 2006). Mouse embryos lacking Oct4 develop to the
blastocyst stage and die after implantation, because of the lack
of pluripotent embryonic cells (Bortvin et al. 2003). The
ablation of Sox2 expression also causes early embryonic
lethality for similar reasons (Avilion et al. 2003).

**Figure 3** Co-localisation analysis of Oct4, Sox2 and CD34 proteins. Panel A and D show the Oct4 and Sox2 positive cells (green and
typical cells were arrowed) in the human pancreatic sections. The sections were re-stained for CD34 protein (red) shown in panel B and
E. Panel C is the merged image of A and B, and F, the merged image of D and E respectively.

**Figure 4** Co-localisation analysis of CD34 and CD133 proteins. Human pancreatic consecutive sections were stained for CK19 (red) and
then re-stained for CD34 and CD133 proteins (green) respectively, showing no co-localisation of the two markers.
The mRNA of Oct4 and Sox2 genes was found in cells from all the 25 human adult pancreases examined, with no obvious segregation to the endocrine or exocrine fractions. Immunohistochemical staining showed that Oct4- and Sox2-expressing cells were scattered within or very close to small ductal structures. They did not co-express CK19, insulin or nestin. Their failure to co-express CK19, the ductal cell marker, despite the fact that they were located in the ductal structures, suggests that the Oct4, Sox2 positive cells are pre-existing cells, although the possibility that Oct4 and/or Sox2 are expressed by duct cells after decreasing expression of CK19 cannot be ruled out. The majority of Sox2\(^{+}\)ve cells co-expressed Oct4 protein, but not all Oct4\(^{+}\)ve cells co-expressed Sox2 protein, possibly due to the low expression level of Sox2 protein; this was consistent with the observation that there was higher expression of Oct4 mRNA than Sox2 (Fig. 1b) and also indicates that they may belong to the same cell population in the adult human pancreas. Expression levels of Oct4 and Sox2 varied between pancreas but their expression was positively correlated with each other. We did not find any predictors of this expression associated with donor criteria, as a trend to an association between higher expression and younger donor age did not reach significance. We may not have included donors young enough to show this correlation.

The localisation of Oct4, Sox2-expressing cells within small duct structures in the adult human pancreas is compatible with observations of endocrine cells budding from duct structures during development and the neogenesis of ductal cells that takes place after pancreatic duct ligation or \(90\%\) pancreatectomy. The plausible explanation is that Oct4 and/or Sox2 positive cells are stem cells retained in adult human pancreas. The presence of stem cells in the islet-enriched pancreatic fractions may be exploited to improve the outcome of human islet transplantation. Equally the ready availability of these cells in the large exocrine cell-enriched fractions obtained during human islet isolation suggests that these may be exploitable as a new source of adult human stem cells to generate \(\beta\)-cell surrogates for cell replacement therapy in diabetes and is certainly worthy of further exploration.

Acknowledgements

We thank Ms H Mandefield and the transplant coordinators of South Thames and King’s College Hospital; Ms Sharon Lehec and the staff of the Dixons Cell Isolation Unit at King’s College Hospital and particularly the relatives of our organ donors. The work was supported by research grants from Juvenile Diabetes Research Foundation International: 1-2004-357 and a grant from the King’s College Hospital Charitable Trust. The authors declare that there is no conflict of interest that would prejudice the impartiality of this scientific work.

References


www.endocrinology-journals.org
Stem cells in human adult pancreases

M Zhao and others

Received in final form 28 August 2007
Accepted 20 September 2007
Made available online as an Accepted Preprint 20 September 2007


